Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

237
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
237
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

213
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
213
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

672
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
672
Tumor Progression02:07

Tumor Progression

6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

635
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
635

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma.

Cell death discovery·2022
Same author

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial.

HemaSphere·2022
Same author

MYC multimers shield stalled replication forks from RNA polymerase.

Nature·2022
Same author

Panel Sequencing of Primary Cutaneous B-Cell Lymphoma.

Cancers·2022
Same author

Vitamin D Receptor Expression Is Significantly Decreased in Bone Metastases Compared to Matched Primary Breast Cancer Tumours.

Cancer investigation·2022
Same author

Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA Consortium.

Cancers·2022
Same journal

Efficacy of Honey Combined with Cryotherapy in the Prevention and Management of Radiation-Induced Oral Mucositis in Patients Undergoing Concurrent Chemoradiotherapy for Head and Neck Cancer.

Oncology research and treatment·2026
Same journal

Three therapeutic modalities for advanced ovarian cancer: real world data from a certified oncological center.

Oncology research and treatment·2026
Same journal

Real world experiences in the treatment of immune thrombocytopenia over a two-year period.

Oncology research and treatment·2026
Same journal

Safety and preliminary activity of neoadjuvant trastuzumab deruxtecan (T-DXd) plus 5-fluorouracil and folinic acid for HER2-positive, resectable esophagogastric adenocarcinoma: Results from the safety run-in cohort of the phase Ib/II UCCL-AIO-STO0124-IKF072 NeoART trial.

Oncology research and treatment·2026
Same journal

Genitourinary Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2025: Advances in Renal Cell Carcinoma and Muscle-invasive Bladder Cancer.

Oncology research and treatment·2026
Same journal

The Role of Regulatory Policies in Shaping Outpatient Cancer Treatment in Germany: A Comparative Perspective.

Oncology research and treatment·2026
See all related articles

Related Experiment Video

Updated: Aug 26, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.3K

Recent Advances in Castleman Disease.

Christian Hoffmann1,2, Marcus Hentrich3, Markus Tiemann4

  • 1ICH Study Center Hamburg, Hamburg, Germany.

Oncology Research and Treatment
|October 11, 2022
PubMed
Summary
This summary is machine-generated.

Castleman disease (CD) is a rare disorder with distinct subtypes. Recent advances clarify diagnosis, treatment, and pathogenesis, particularly for idiopathic multicentric CD (iMCD).

Keywords:
Castleman diseaseHHV-8Multicentric CDSiltuximabUnicentric CD

More Related Videos

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

987
Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

3.5K

Related Experiment Videos

Last Updated: Aug 26, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.3K
Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

987
Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

3.5K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Castleman disease (CD) comprises rare lymphoid hyperplasias.
  • Unicentric CD (UCD) is localized and typically curable.
  • Multicentric CD (MCD) is systemic, potentially fatal, and linked to IL-6 dysregulation.

Purpose of the Study:

  • To summarize recent diagnostic and therapeutic advances in Castleman disease.
  • To provide novel insights into the pathogenesis of CD.
  • To highlight the heterogeneity within human herpesvirus-8 negative MCD.

Main Methods:

  • Review of recent literature on Castleman disease.
  • Analysis of diagnostic criteria and treatment strategies.
  • Synthesis of current understanding of disease mechanisms.

Main Results:

  • Castleman disease classification includes UCD, HHV-8+ MCD, and iMCD.
  • iMCD is not a single entity and presents distinct clinical variants.
  • International guidelines for iMCD and UCD diagnosis and treatment exist.

Conclusions:

  • Distinguishing between HHV-8+ MCD and iMCD is crucial for treatment.
  • Further research is needed to understand the heterogeneity of iMCD.
  • Established guidelines aid in managing UCD and iMCD.